07.06.2013 - US-based algae biofuel and omega-3 oil giant Cellana has signed a multi-year collaboration with Finnish Nesté Oil, the global #1 for bio-diesel.
Under the term of the agreement, Neste Oil will purchase crude algal oil from Cellana, which the company produces in commercial-scale algae biorefineries. The non-exclusive agreement is contingent on Cellana's future production capacity and on compliance with future biofuel legislation in the EU and US, amongst other factors.
"We want to support R&D efforts on new, sustainably produced raw materials and increased production of algae oil, which is one of the most interesting future alternatives in this area. Studies have already shown that algae oil can be used successfully in our NExBTL process," says Neste Oil's Senior Vice President, Technology, Lars Peter Lindfors.
"The off-take agreement with Cellana allows us access to commercial-scale volumes of cost-competitive algae oil in the future. This new agreement fits very well with our strategy aimed at extending the range of feedstocks we use for NExBTL renewable fuel." Samples have shown that Cellana is able to produce algae oil suitable for renewable fuel production by Neste Oil.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more